In this context, the present study aimed to reinvestigate the link between habitual caffeine intake with CSF levels of amyloid Aβ40, Aβ42, tau, and p‐tau in the clinically defined Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort, including non‐amnestic MCI (naMCI), amnestic MCI (aMCI), and AD patients. This evidence concerns the gene MAPT and Alzheimer disease.